#BEGIN_DRUGCARD DB06285

# AHFS_Codes:
Not Available

# ATC_Codes:
H05AA02

# Absorption:
Bioavailability is 95% following subcutaneous injection.

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Apthela
Forsteo
Forteo
Fortessa
Opthia
Optia
Optiah
Zalectra
Zelletra

# CAS_Registry_Number:
52232-67-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C181H291N55O51S2

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>Parathyroid hormone precursor - Homo sapiens (1-34)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

# Creation_Date:
2008-03-19 10:21:24 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.

# Dosage_Forms:
Solution	Subcutaneous

# Drug_Category:
Bone Density Conservation Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
16872263	Close P, Neuprez A, Reginster JY: Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother. 2006 Aug;7(12):1603-15.
18319498	Stroup J, Kane MP, Abu-Baker AM: Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9.

# Drug_Type:
Approved
Biotech
Investigational

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Teriparatide

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D06078

# LIMS_Drug_ID:
6286

# Mechanism_Of_Action:
Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
4117.7150

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451620

# Pharmacology:
Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB06285

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
PTH1-34 nasal spray
ViaDerm hPTH 1-34
ViaDerm-hPTH (1-34)
hPTH 1-34
synthetic human parathyroid hormone 1-34

# Synthesis_Reference:
Not Available

# Toxicity:
Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.

# Update_Date:
2012-06-14 15:28:40 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Teriparatide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PTHR1

# Drug_Target_1_GenBank_ID_Gene:
BC112247

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
PTH1R

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10913300	Grauschopf U, Lilie H, Honold K, Wozny M, Reusch D, Esswein A, Schafer W, Rucknagel KP, Rudolph R: The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. Biochemistry. 2000 Aug 1;39(30):8878-87.
7701349	Schipani E, Kruse K, Juppner H: A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science. 1995 Apr 7;268(5207):98-100.
7745008	Schipani E, Weinstein LS, Bergwitz C, Iida-Klein A, Kong XF, Stuhrmann M, Kruse K, Whyte MP, Murray T, Schmidtke J, et al.: Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. J Clin Endocrinol Metab. 1995 May;80(5):1611-21.
8386612	Schipani E, Karga H, Karaplis AC, Potts JT Jr, Kronenberg HM, Segre GV, Abou-Samra AB, Juppner H: Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology. 1993 May;132(5):2157-65.
8397094	Schneider H, Feyen JH, Seuwen K, Movva NR: Cloning and functional expression of a human parathyroid hormone receptor. Eur J Pharmacol. 1993 Jul 15;246(2):149-55.
8703170	Schipani E, Langman CB, Parfitt AM, Jensen GS, Kikuchi S, Kooh SW, Cole WG, Juppner H: Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med. 1996 Sep 5;335(10):708-14.
9737850	Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF: Binding domain of human parathyroid hormone receptor: from conformation to function. Biochemistry. 1998 Sep 15;37(37):12737-43.

# Drug_Target_1_HGNC_ID:
HGNC:9608

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5986

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
66361

# Drug_Target_1_Name:
Parathyroid hormone/parathyroid hormone-related peptide receptor

# Drug_Target_1_Number_of_Residues:
593

# Drug_Target_1_PDB_ID:
1BL1

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00002	7tm_2
PF02793	HRM

# Drug_Target_1_Protein_Sequence:
>Parathyroid hormone/parathyroid hormone-related peptide receptor
MGTARIAPGLALLLCCPVLSSAYALVDADDVMTKEEQIFLLHRAQAQCEKRLKEVLQRPA
SIMESDKGWTSASTSGKPRKDKASGKLYPESEEDKEAPTGSRYRGRPCLPEWDHILCWPL
GAPGEVVAVPCPDYIYDFNHKGHAYRRCDRNGSWELVPGHNRTWANYSECVKFLTNETRE
REVFDRLGMIYTVGYSVSLASLTVAVLILAYFRRLHCTRNYIHMHLFLSFMLRAVSIFVK
DAVLYSGATLDEAERLTEEELRAIAQAPPPPATAAAGYAGCRVAVTFFLYFLATNYYWIL
VEGLYLHSLIFMAFFSEKKYLWGFTVFGWGLPAVFVAVWVSVRATLANTGCWDLSSGNKK
WIIQVPILASIVLNFILFINIVRVLATKLRETNAGRCDTRQQYRKLLKSTLVLMPLFGVH
YIVFMATPYTEVSGTLWQVQMHYEMLFNSFQGFFVAIIYCFCNGEVQAEIKKSWSRWTLA
LDFKRKARSGSSSYSYGPMVSHTSVTNVGPRVGLGLPLSPRLLPTATTNGHPQLPGHAKP
GTPALETLETTPPAMAAPKDDGFLNGSCSGLDEEASGPERPPALLQEEWETVM

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-26

# Drug_Target_1_Specific_Function:
This is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system

# Drug_Target_1_SwissProt_ID:
Q03431

# Drug_Target_1_SwissProt_Name:
PTH1R_HUMAN

# Drug_Target_1_Synonyms:
PTH/PTHr receptor
PTH/PTHrP type I receptor
Parathyroid hormone/parathyroid hormone-related peptide receptor precursor

# Drug_Target_1_Theoretical_pI:
8.05

# Drug_Target_1_Transmembrane_Regions:
189-212
220-239
283-306
321-342
362-382
410-428
441-463

#END_DRUGCARD DB06285
